Patents by Inventor John E. Macor

John E. Macor has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • (R)-3-((3S,4S)-3-FLUORO-4-(4-HYDROXYPHENYL)PIPERIDIN-1-YL)-1-(4-METHYLBENZYL)PYRROLIDIN-2-ONE AND ITS PRODRUGS FOR THE TREATMENT OF PSYCHIATRIC DISORDERS
    Publication number: 20180104265
    Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the NR2B NMDA receptor and may be useful for the treatment of various disorders of the central nervous system.
    Type: Application
    Filed: December 19, 2017
    Publication date: April 19, 2018
    Inventors: Lorin A. Thompson, III, John E. Macor
  • Quinoline-based kinase inhibitors
    Patent number: 9932320
    Abstract: The present disclosure is generally directed to compounds of formula (I) which can inhibit AAKI (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAKI.
    Type: Grant
    Filed: January 23, 2015
    Date of Patent: April 3, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: Richard A. Hartz, Vijay T. Ahuja, John E. Macor, Joanne J. Bronson, Bireshwar Dasgupta, Carolyn Diane Dzierba, Susheel Jethanand Nara, Maheswaran Sivasamban Karatholuvhu
  • Biaryl kinase inhibitors
    Patent number: 9902722
    Abstract: The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.
    Type: Grant
    Filed: April 1, 2015
    Date of Patent: February 27, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: Guanglin Luo, Ling Chen, Carolyn Diane Dzierba, Jonathan L. Ditta, John E. Macor, Joanne J. Bronson
  • SELECTIVE NR2B ANTAGONISTS
    Publication number: 20180000807
    Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system.
    Type: Application
    Filed: September 15, 2017
    Publication date: January 4, 2018
    Inventors: Dalton King, Lorin A. Thompson, III, Jianliang Shi, Srinivasan Thangathirupathy, Jayakumar Sankara Warrier, Imadul Islam, John E. Macor
  • [1,2,4]TRIAZOLO[1,5-a]PYRIDINYL SUBSTITUTED INDOLE COMPOUNDS
    Publication number: 20180000790
    Abstract: Disclosed are compounds of Formula (I) or a salt thereof, wherein R1, R2, R3, R4, R5, m, n, and p are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.
    Type: Application
    Filed: June 27, 2017
    Publication date: January 4, 2018
    Inventors: Alaric J. Dyckman, Dharmpal S. Dodd, Tasir Shamsul Haque, Louis J. Lombardo, John E. Macor, Christopher P. Mussari, Laxman Pasunoori, Sreekantha Ratna Kumar, Trevor C. Sherwood, Shoshana L. Posy, Ramesh Kumar Sistla, Subramaya Hegde, Anupama Ramachandra
  • CARBAZOLE DERIVATIVES
    Publication number: 20170362176
    Abstract: Disclosed are compounds of Formula (I): (I) or a salt thereof, wherein Q, R1a, R1b, R2a, R2b, R3, R4, R5a, R5b, R6a, R6c, R7a, R7b, R7c, and R7d are defined herein. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.
    Type: Application
    Filed: October 23, 2015
    Publication date: December 21, 2017
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Saleem Ahmad, Douglas G. Batt, Qingjie Liu, John E. Macor, Joseph A. Tino, Scott Hunter Watterson
  • (R)-3-((3S,4S)-3-FLUORO-4-(4-HYDROXYPHENYL)PIPERIDIN-1-YL)-1-(4-METHYLBENZYL)PYRROLIDIN-2-ONE AND ITS PRODRUGS FOR THE TREATMENT OF PSYCHIATRIC DISORDERS
    Publication number: 20170340653
    Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the NR2B NMDA receptor and may be useful for the treatment of various disorders of the central nervous system.
    Type: Application
    Filed: August 17, 2017
    Publication date: November 30, 2017
    Inventors: Lorin A. Thompson, III, John E. Macor
  • Substituted pyridine derivatives useful as GSK-3 inhibitors
    Patent number: 9809573
    Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands, antagonists of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system.
    Type: Grant
    Filed: November 3, 2014
    Date of Patent: November 7, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Guanglin Luo, Ling Chen, Gene M. Dubowchik, Swanee E. Jacutin-Porte, Prasanna Sivaprakasam, John E. Macor
  • Selective NR2B Antagonists
    Publication number: 20170258777
    Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system.
    Type: Application
    Filed: May 25, 2017
    Publication date: September 14, 2017
    Inventors: Dalton King, Lorin A. Thompson, III, Jianliang Shi, Srinivasan Thangathirupathy, Jayakumar Sankara Warrier, Imadul Islam, John E. Macor
  • HETEROCYCLIC KINASE INHIBITORS
    Publication number: 20170260145
    Abstract: The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.
    Type: Application
    Filed: July 27, 2015
    Publication date: September 14, 2017
    Inventors: Carolyn Diane Dzierba, Joanne J. Bronson, John E. Macor, Bireshwar Dasgupta, Susheel Jethanand Nara, Vivekananda M Vrudhula, Senliang Pan, Richard A. Hartz, Ramkumar Rajamani
  • INDOLE CARBOXAMIDE COMPOUNDS
    Publication number: 20170260160
    Abstract: Disclosed are compounds of Formula (I): or a salt thereof, wherein: X is CR4 or N; R1, R2, R3, R4, and A are defined herein. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.
    Type: Application
    Filed: May 30, 2017
    Publication date: September 14, 2017
    Inventors: Qingjie Liu, Scott Hunter Watterson, Douglas G. Batt, Saleem Ahmad, Myra Beaudoin Bertrand, Hua Gong, Weiwei Guo, John E. Macor, Khehyong Ngu, Andrew J. Tebben, Joseph A. Tino
  • QUINAZOLINE-BASED KINASE INHIBITORS
    Publication number: 20170239249
    Abstract: The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.
    Type: Application
    Filed: September 25, 2015
    Publication date: August 24, 2017
    Inventors: Richard A. HARTZ, Vijay T. AHUJA, John E. MACOR, Joanne J. BRONSON, Bireshwar DASGUPTA, Carolyn Diane DZIERBA, Susheel Jethanand NARA, Maheswaran Sivasamban KARATHOLUVHU
  • Pyrrolotriazine kinase inhibitors
    Patent number: 9737542
    Abstract: The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.
    Type: Grant
    Filed: October 8, 2014
    Date of Patent: August 22, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Carolyn Diane Dzierba, Bireshwar Dasgupta, John E. Macor, Joanne J. Bronson, Ramkumar Rajamani, George N. Karageorge
  • Triazolopyridine ether derivatives and their use in neurological and pyschiatric disorders
    Patent number: 9738642
    Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds modulate the mGluR2 receptor and may be useful for the treatment of various disorders of the central nervous system.
    Type: Grant
    Filed: September 18, 2014
    Date of Patent: August 22, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Lawrence R. Marcin, Mendi A. Higgins, Joanne J. Bronson, F. Christopher Zusi, John E. Macor, Min Ding
  • (R)-3-((3S,4S)-3-FLUORO-4-(4-HYDROXYPHENYL)PIPERIDIN-1-YL)-1-(4-METHYLBENZYL)PYRROLIDIN-2-ONE AND ITS PRODRUGS FOR THE TREATMENT OF PSYCHIATRIC DISORDERS
    Publication number: 20170216325
    Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the NR2B NMDA receptor and may be useful for the treatment of various disorders of the central nervous system.
    Type: Application
    Filed: April 18, 2017
    Publication date: August 3, 2017
    Inventors: Lorin A. Thompson, III, John E. Macor
  • GSK-3 inhibitors
    Patent number: 9718804
    Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds to treat disorders associated with GSK-3.
    Type: Grant
    Filed: November 3, 2014
    Date of Patent: August 1, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Guanglin Luo, Ling Chen, Gene M. Dubowchik, Swanee E. Jacutin-Porte, Vivekananda M. Vrudhula, Senliang Pan, Prasanna Sivaprakasam, John E. Macor
  • Aryl amide-based kinase inhibitors
    Patent number: 9708337
    Abstract: The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.
    Type: Grant
    Filed: February 6, 2014
    Date of Patent: July 18, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Vivekananda M. Vrudhula, Carolyn Diane Dzierba, Joanne J. Bronson, John E. Macor, Susheel Jethanand Nara, Ramkumar Rajamani, Maheswaran Sivasamban Karatholuvhu
  • BIARYL KINASE INHIBITORS
    Publication number: 20170183340
    Abstract: The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.
    Type: Application
    Filed: April 1, 2015
    Publication date: June 29, 2017
    Inventors: Guanglin Luo, Ling Chen, Carolyn Diane Dzierba, Jonathan L. Ditta, John E. Macor, Joanne J. Bronson
  • Oxazolidinones as modulators of mGluR5
    Patent number: 9688669
    Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands, agonists and partial agonists for the mGluR5 receptor and may be useful for the treatment of various disorders of the central nervous system.
    Type: Grant
    Filed: October 6, 2014
    Date of Patent: June 27, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Andrew P. Degnan, Darrell Maxwell, Matthew D. Hill, Haiquan Fang, Michael F. Parker, Fukang Yang, Joanne J. Bronson, John E. Macor
  • (R)-3-((3S,4S)-3-FLUORO-4-(4-HYDROXYPHENYL)PIPERIDIN-1-YL)-1-(4-METHYLBENZYL)PYRROLIDIN-2-ONE AND ITS PRODRUGS FOR THE TREATMENT OF PSYCHIATRIC DISORDERS
    Publication number: 20170065573
    Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the NR2B NMDA receptor and may be useful for the treatment of various disorders of the central nervous system.
    Type: Application
    Filed: November 21, 2016
    Publication date: March 9, 2017
    Inventors: Lorin A. Thompson, III, John E. Macor